IF this technology works, the revenue from the doses will be inconsequential. The fact that NGIO/GNBT will have proven that they have a process to quickly develop a viral vaccine that can be produced synthetically will make NGIO/GNBT worth billions - if not as a stand alone company, then as a takeover/buyout target by some large pharma.

And that won't even account for the cancer therapy potential of AE37, nor any of the other initiatives that GNBT is now working on.

Theoretically, in 3 months, this could literally affect the world.